Guest Blog Post by CBD-Reviewed
Cannabidiol, better known as CBD, is one of more than 100 naturally occurring compounds called cannabinoids found in the plant Cannabis sativa. Unlike its counterpart tetrahydrocannabinol (THC) and certain pharmaceutical drugs, it’s not psychoactive, which means it doesn’t induce euphoria, sedation or an altered state of mind. This property combined with its pain-reducing effects makes it appealing to those seeking relief from pain and other symptoms. A new study finds that the CBD market could generate $16 billion by 2025. This is a huge jump from the estimated retail spend between $600 million and $2 billion on CBD consumer products in 2018.
2. Our Study
A global survey conducted by CBD-Reviewed.com spanning 8 countries comprising both men and women who are active users of CBD has presented some interesting results. Placed on CBD platforms and forums, various CBD sites and social media groups, the survey was conducted over 4 weeks. Of the 152 respondents, a majority used CBD more than 8 times per week (38%), 6-7 times a week (24%), and around between 2-5 times a week (7-15%). Almost half the users were employed while the others were self-employed or students.
CBD-Reviewed zeroed in on key people and experts who are actively involved in the study and application of CBD and other cannabinoids. The team then reached out to these authoritative sources and conducted detailed and exclusive interviews via phone and email to obtain valuable insights, opinions and the latest trends associated with CBD per their varied expertise. The platform also helped the interviewees reach a massive CBD community who would benefit immensely from their inputs.
3. CBD: What’s Your Choice?
CBD oil (63.5%) and vaping (30.4%) were the most preferred forms of CBD usage followed by lotions, edibles, gummies, pills, and tea. 63.4% of them bought CBD online. CBD oil is used as a substitute for prescription medications. Diluted with an oil, the hemp extract is either sprayed on the inside of the cheek or placed under the tongue where it’s absorbed directly into the bloodstream. Though vaping allows nearly 4 times the CBD to enter circulation with a maximum bioavailability of roughly 50-60% compared to the bioavailability of CBD taken orally (15%). Vaping activates CBD in the body in a much shorter time since it enters the lungs directly instead of passing through the gut and liver.
What the Experts Say
“The effects of consuming CBD edibles may last longer than the effects of inhaling CBD because the CBD is processed in two different ways by the body. Inhalation involves taking the compounds into the lungs which directly infuses into the bloodstream, while edibles need to make their way through the digestive system before being processed by the liver and then distributed throughout the body. Cooking with CBD oil can be safe if you are using a safe and reliable product. You want to ensure you are not heating the CBD product over 240 degrees F when cooking or you may destroy the cannabinoids.”
“CBD is now an approved therapeutic drug (e.g. against some rare and untreatable forms of pediatric epilepsy). In order to produce therapeutic effects, it needs to be administered orally at doses and formulations that are difficult to achieve in “edibles. I am not of the opinion that CBD, like other therapeutic drugs, should be used as a food supplement. We have been investigating “multi-target” drugs, and the non-euphoric cannabinoids, such as CBD, represent a very nice example of this strategy.”
Dr. Vincenzo Di Marzo
4. CBD: A Multi-Pronged Therapeutic
Survey results also suggested the wide-ranging therapeutic applications of CBD with anxiety disorders, chronic pain, inflammation, insomnia, and arthritis management being the most popular. Other lesser popular reasons for CBD usage included seizures, diabetes, cancer, depression, migraines, and acne.
According to a study released in Cannabis and Cannabinoid Research, 62% of CBD users reported using CBD to take care of a medical condition, the top 3 being pain, anxiety, and depression. Short-term use of CBD oil could reduce the levels of spasticity and muscle spasms in those with Multiple Sclerosis (MS). A separate study in the Journal of Experimental Medicine suggests that using CBD can reduce pain and inflammation making it an effective treatment for chronic pain in adults.
What the Experts Say
“CBD is now a therapeutic drug approved by the FDA, so, in a way, it is as traditional as other natural product-derived drugs. Considering that most disorders are multi-factorial, i.e. they involve several mechanisms in different phases of disease, its benefits are probably due to its capability of modulating several molecular targets.CBD interacts with several receptors and proteins with known pharmacological action and biological role. This versatility possibly explains why it known to be efficacious in several preclinical studies in a plethora of disorders, and possibly why it is relatively safe in humans up to high doses.”
Dr. Vincenzo Di Marzo
5. CBD: All-Natural Plant Medicine
It came as no surprise that all the respondents believe in the benefits of CBD, recommend it, think it should be legalized in their country and will be in the next 5 years. Buying CBD is federally legal as long as it doesn’t contain more than 0.3% THC. However, buyers need to be aware of local cannabis laws that may impose specific restrictions. The origin of hemp that is the source of CBD, certificate of analysis (COA) that checks for potency and contaminants, testing methods that need to be validated by national regulatory organizations, and the total amount and dosage of CBD and THC need to be clearly listed on the label. (https://www.pbs.org/newshour/science/is-cbd-legal-heres-what-you-need-to-know-according-to-science)
What the Experts Say
“Except for rare examples of strictly standardized extracts, medical and pharmacological research should focus on pure cannabinoids or their combinations rather than on cannabis extracts of dubious source and no reproducible way of producing them, let alone cannabis (marijuana) smoking. Of course, some very ill people cannot wait for the long times of drug development and are therefore led to use such preparations. Therefore, there should be more and more funds dedicated to cannabinoid research in order to accelerate as much as possible the process of new drug development from these compounds.”
Dr. Vincenzo Di Marzo
6. CBD: The Not So Good Part
Fatigue (38.4%), decreased appetite (17.8%), and somnolence (12.3%) were reported to be the most common side effects of using CBD with a minority reporting diarrhea and insomnia. According to a report in Cannabis and Cannabinoid Research, common side effects of CBD include diarrhea, drowsiness, nausea, fatigue, irritability, dry mouth, cloudy thoughts, and wakefulness. It can also increase the levels of the blood thinner coumadin and certain other medications in the blood.
What the Experts Say
“CBD can have side effects including dizziness, drowsiness, or increased anxiety. Just like with medical nutrition therapy, cannabis therapeutics have health benefits and risks that are individual to each unique person. Working with a healthcare provider who will provide a personalized approach is the best way to ensure you are maximizing the health benefits and minimizing the health risks of using cannabis from a nutritional perspective.”
“CBD is pretty safe, even in children, but as with all therapeutic drugs that show efficacy, side effects have been reported. These are usually mild, in some case transitory, but could be disturbing in the long run for some patient populations. In general, CBD is a very well tolerated drug. In a pediatric population, CBD has been reported to induce somnolence and some mild diarrhea. Other minor side effects have also been reported.”
Dr. Vincenzo Di Marzo
7. CBD: Moderation and Regulation are Key
70% of the participants thought CBD was safe to use without limit while 30% felt it could be dangerous to use without limit. Since CBD is primarily marketed and sold as a supplement, not a medication, it may contain unknown elements and not the active ingredients at the dose listed on the label. Currently, the FDA doesn’t regulate the safety and purity of dietary supplements. Since the most effective therapeutic dose of CBD for any particular medical condition is unknown, it presents a safety concern.
What the Experts Say
“Cannabis is not a magic pill, but rather a healing tool that can be used as a part of a greater holistic centered lifestyle. Adding CBD to a poor diet will not correct the poor diet, just as adding healthy foods to the diet of an emotionally or mentally stressful individual will not correct the underlying cause. It is the balance of many forces that creates wellness. CBD should be used thoughtfully and responsibly.”
8. CBD vs Marijuana: Not Exactly A Case of Good Child vs Bad Child
86% of those who used CBD has already tried marijuana for social, medical, and spiritual use. 75% of the respondents felt different using CBD when compared to using marijuana. Though both CBD and THC are present in marijuana, recreational users of marijuana seek the high associated with THC. Medical marijuana has minimal THC and is CBD dominant. This CBD is taken from the hemp plant that is closely related to the marijuana plant that THC is extracted from. THC has potential applications in treating glaucoma, muscle spasticity, low appetite, and insomnia. (https://www.medicalnewstoday.com/articles/325871.php)
What the Experts Say
“There is no such thing as “one cannabis,” but several different types, whose properties strictly depend on their chemical components, i.e. in most cases, the cannabinoids. There are several (>100) such compounds, but only one of them is known to be responsible for the psychotropic effects of marijuana, which is prepared only from the flowers of those varieties of cannabis that contain high levels of THC (in the form of its acid precursor). Therefore: 1) there is not only one cannabis, 2) cannabis does not equate marijuana, and 3) cannabinoids do not equate THC.”
Dr. Vincenzo Di Marzo
About Emily Kyle
Emily Kyle is a Registered Dietitian Nutritionist and a Certified Holistic Cannabis Practitioner who adopts a holistic healthcare approach combining medical nutrition therapy and cannabis therapeutics. She uses her education to serve those with autoimmune and inflammatory conditions with a holistic healthcare approach combining medical nutrition therapy and cannabis therapeutics. Emily has been taking a combination of all cannabinoids daily for the past 10 years to manage anxiety and depression.
About Dr. Vincenzo Di Marzo
Dr. Vincenzo Di Marzo is the Research Director at the ICB-CNR in Pozzuoli Coordinator of the Endocannabinoid Research Group in Naples, an Associate Research Director at the National Research Council in Italy and the holder of a Canada Excellence Research Chair at Université Laval in Quebec City, Canada. He also directs a Joint International Research Unit on Chemical and Biomolecular Research on the Microbiome between Université Laval and the CNR.
Harborside Inc. Announces C$20 Million Private Placement of Equity Units and Provides 2021 Outlook
OAKLAND, Calif. and TORONTO, Jan. 19, 2021 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, today announced a brokered private placement of units (the “Units”) of the Company (the “Offering”) at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$20 million with approximately C$9.0 million of commitment from Entourage Effect […]
The post Harborside Inc. Announces C$20 Million Private Placement of Equity Units and Provides 2021 Outlook appeared first on CannabisFN.
January 20th, 2021
News, Top News
OAKLAND, Calif. and TORONTO, Jan. 19, 2021 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, today announced a brokered private placement of units (the “Units”) of the Company (the “Offering”) at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$20 million with approximately C$9.0 million of commitment from Entourage Effect Capital, LLC (“Entourage”), one of the largest shareholders of Harborside.
The Company has granted the Agents (as defined below) an option to sell up to an additional 15% of the Units in the Offering, exercisable in whole or in part at any time prior to closing of the Offering.
Each Unit issued to non-residents of the United States (an “SVS Unit”) will be comprised of one subordinate voting share of the Company (the “Subordinate Voting Shares”) and one Subordinate Voting Share purchase warrant (each a “Warrant”) of the Company. Each Warrant will be exercisable to acquire one Subordinate Voting Share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering (the “Closing Date”) at an exercise price of C$3.69 per Warrant Share, subject to adjustment and acceleration in certain events.
All investors that are considered residents of the United States under the United States Securities Exchange Act of 1934, will be issued units comprised of multiple voting shares of the Company (the “Multiple Voting Shares”) and Multiple Voting Share purchase warrants of the Company, which will be based on the same economic equivalency of each Multiple Voting Share converting into 100 Subordinate Voting Shares.
“We are continuing to expand our footprint in the robust California cannabis market, delivering our best-in-class service and the high-quality product selection that Harborside is known for,” said Matthew Hawkins, Chairman of Harborside. “California is one of the largest cannabis markets in the world and Harborside has more than a decade of market success for our team to build on. I would like to thank our current and new shareholders for their overwhelming support of our growth strategy. This additional capital will solidify our balance sheet and provide a platform for us to continue to consolidate in the California market through accretive M&A transactions.”
The Company expects to use the net proceeds from the Offering for general corporate and working capital purposes.
ATB Capital Markets and Beacon Securities Limited will act as co-lead agents to the Offering (the “Agents”). The Company has agreed to pay the Agents a cash commission payable on the Closing Date equal to 6.0% of the aggregate gross proceeds of the Offering (the “Cash Commission”), and to issue the Agents warrants (the “Broker Warrants”), exercisable to acquire, within 12 months from the Closing Date, in the aggregate, that number of Subordinate Voting Shares (the “Broker Warrant Shares”) that is equal to 6.0% of the aggregate number of Units sold in the Offering, at an exercise price of C$2.55 per Broker Warrant Share. An adjusted commission structure will apply on select president’s list investors coordinated by the Company. Subject to customary closing conditions, including applicable CSE approvals, the Offering is expected close on or about February 9, 2021 (the “Closing Date”), or such other date as the Company and the Agents may agree.
As certain insiders and other related parties of the Company will be participating in the Offering, it is deemed to be a “related party transaction” as defined under Multilateral Instrument 61-101—Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61- 101 (pursuant to subsections 5.5(a) and 5.7(a)) as the fair market value of the securities distributed to, and the consideration received from, related parties will not exceed 25% of the Company’s market capitalization.
2020 Preliminary Results and 2021 Outlook(1)(2)
The Company is also pleased to provide the following update of guidance for 2020 along with guidance for 2021.
For the full year ended 2020, the Company is expecting gross revenues in line with previously issued guidance of approximately $61 – 63 million, and positive EBITDA. For the full year ended 2021, the Company expects standalone gross revenues of between $68 – $72 million. The increase in revenues for 2021 is expected to be derived from improved pricing in retail along with continued increases in both flower yields and processing efficiencies in Harborside’s wholesale operations. As well, the Company expects a 2021 full year of Adjusted EBITDA(3) in the range of 15 – 17% of revenues, compared to the previously disclosed 2020 expectation of Adjusted EBITDA(3) in the range of 8 – 10% of revenues. Management expects to attain this higher level of Adjusted EBITDA(3) in 2021 through more efficient procurement of goods sold and stronger cost discipline on overhead spend.
Intention to Divest of Oregon Assets(1)
Through a review of the Company’s existing retail portfolio, management has decided to explore the divestiture of its one retail dispensary operating as Terpene Station in Eugene, Oregon (the “Oregon Assets”) as part of the Company’s continued efforts to focus on the California market. The Company has not entered into any agreements, binding or non-binding, to divest of the Oregon Assets as of this date. Further, the Company has not established a definitive timeline to complete such divestiture, and no decisions related to the divestiture have been reached at this time. There can be no assurance as to what, if any, transaction might be pursued by the Company as a result of its intention to divest the Oregon Assets. The Company does not intend to comment further with respect to the divestiture unless and until it determines that additional disclosure is appropriate in the circumstances and in accordance with the requirements of applicable securities laws.
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. In 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.
About Entourage Effect Capital:
Entourage Effect Capital, LLC, formerly known as Cresco Capital Partners, LLC, is a United States private investment firm, dedicated to investing in the cannabis industry. The firm’s mission is to actively leverage its sector and investment experience, networks, and investment process, and to identify, invest and accelerate high quality emerging growth companies. Entourage was formed in 2014 and is based in Dallas, Texas.
Non-IFRS Measures, Reconciliation and Discussion
This press release may contain references to “Adjusted EBITDA”, which is a non-IFRS financial measures.
Adjusted EBITDA is a measure of the Company’s overall financial performance and is used as an alternative to earnings or net income in some circumstances. Adjusted EBITDA is essentially net income (loss) with interest, taxes, depreciation and amortization, non-cash adjustments and other unusual items added back. This measure can be used to analyze and compare profitability among companies and industries, as it eliminates the effects of financing and capital expenditures. It is often used in valuation ratios and can be compared to enterprise value and revenue. This measure does not have any standardized meaning according to IFRS and therefore may not be comparable to similar measures presented by other companies.
There are no comparable IFRS financial measures presented in Harborside’s financial statements. Reconciliations of the supplemental non-IFRS measures are presented in the Company’s management’s discussion and analysis for September 30, 2020. These non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. The Company believes that these supplemental measures provide information which is useful to shareholders and investors in understanding our performance and may assist in the evaluation of the Company’s business relative to that of its peers.
These non-IFRS financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the IFRS financial measures presented in the Company’s financial statements. For more information, please see “Use of Non-IFRS Measures” and “Non-IFRS Measures” in the Company’s management’s discussion and analysis for September 30, 2020, which is available under the Company’s profile on www.sedar.com.
- This is forward-looking information and based on a number of assumptions. See “Cautionary Note Regarding Forward-Looking Information”.
- These targets, and the related assumptions, involve known and unknown risks and uncertainties that may cause actual results to differ materially. While Harborside believes there is a reasonable basis for these targets, such targets may not be met. These targets represent forward-looking information. Actual results may vary and differ materially from the targets. See “Cautionary Note Regarding Forward-Looking Information” and “Assumptions” below.
- This is a non-IFRS reporting measure. For a reconciliation of this to the nearest IFRS measure, see “Use of Non- IFRS Measures” and “Non-IFRS Measures” in the Company’s management discussion and analysis for September 30, 2020.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward- looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to future company performance, growth, profitability, production capacity and gain in market share, the Company’s corporate strategy moving forward, expected use of proceeds from the Offering, the anticipated Closing Date, the information under the heading “2021 Outlook”, the Company’s intention to divest the Oregon Assets.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political, social and environmental uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company, through several of its subsidiaries, is indirectly involved in the manufacture, possession, use, sale, and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States. Local state laws where the Company operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Listing Statement dated May 30, 2019, and in the Company’s management’s discussion and analysis for the period ended September 30, 2020, filed under the Company’s profile on SEDAR at www.sedar.com.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
In developing the financial guidance set forth above, Harborside made the following assumptions and relied on the following factors and considerations:
- The targets are based on Harborside’s historical results including its year-to-date consolidated results of operations.
- The targets are subject to cultivation improvement plans anticipated to come online during 2021.
- Targeted revenue at our retail dispensaries through the end of the year is based on our YTD results.
- Both retail and wholesale revenue sustainability and growth depend on a variety of factors, including among other things, location, competition, legal and regulatory requirements. Prices are projected forward at recently realized wholesale and retail prices.
- Cost of goods sold, before taking into account the impact of value changes in biological assets (which are non- cash in nature, and, accordingly, are excluded from calculations of Adjusted EBITDA), have been projected based on estimated costs of production and capacity available from a vertically integrated supply chain. Cost of goods sold relating to inventory purchased from third parties have been projected in line with historical levels.
- Selling, general and administrative expenses through the end of 2021 are assumed to decrease as a percentage of revenues due to inherent scalability of selling, general and administrative expenses and our cost cutting initiatives outlined above. Additionally, total selling, general and administrative expenses include an allocation for corporate overhead and public company costs.
The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Harborside Inc.
For further information: Company Contact: Harborside Inc., Peter Bilodeau, Interim CEO, (519) 919-6500; Investor Contact: MATTIO Communications, Rob Kelly, [email protected]com; Media Contact: MATTIO Communications, [email protected]
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Michigan Dispensary Gives Cannabis for COVID Vaccinations
The ‘Pot for Shots’ initiative was launched to encourage Michiganders to get vaccinated.
California Hasn’t Seen An Increase In Young Adult Cannabis Use Since Legalization
A recently published study found no significant increase in youth cannabis use since legalization in California.
What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?
New York Small Business Cooperative License
New York Cannabis Distributor License
Investors in This Cannabis Stock Are Leaving $800 Million on the Table
The USDA Has Released Its Final Rule on Hemp Regulation
New York Cannabis Delivery License
What is Delta-8 THC? Everything You Need to Know
What’s New With Cannabis Stocks for the Week Ending 01/15/21
Cannabis Nursery in New York
New York’s Marijuana Cultivation License
Optical Coherence Tomography Findings in Cannabis Users
Virginia Subcommittee on Marijuana Forms to Debate Legalization Bill
CBD News: Clint Eastwood files third suit against CBD companies, saying they’re falsely claiming endorsement
USDA Issues Final Rule On Hemp
France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…
CBD News Roundup: FDA Provides Framework for Future CBD Research
New York’s Adult-Use Processor License
New York Cannabis License Application
Airfield Supply Co. And Kiva Confections Launch Breast Cancer Awareness Campaign
Some Oddly Specific Predictions About Films You Should Keep an Eye Out For This Year
Numinus Announces Grant of Stock Options
EGF Theramed Raises $352,502 in First Tranche of Private Placement
Antioxidant Function of Phytocannabinoids: Molecular Basis of Their Stability and Cytoprotective Properties under UV-irradiation
Billy Bands’ Rap Journey Has Only Just Begun
New York Cannabis Microbusiness License
CBD News: NIHC chairman appointed to board advising U.S. on trade policy
New York Cannabis Dispensary License
Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
Alcanna to Spin Out Cannabis Business and Pursue Value Segment Strategy
Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units
News1 week ago
Pure Harvest Bolsters Corporate Team with Key Additions
Heartland6 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!
Heartland1 week ago
Commentary: LRP1 Is a Master Regulator of Tau Uptake and Spread